CN110812305A - Anti-wrinkle eye cream and preparation process thereof - Google Patents
Anti-wrinkle eye cream and preparation process thereof Download PDFInfo
- Publication number
- CN110812305A CN110812305A CN201911299795.XA CN201911299795A CN110812305A CN 110812305 A CN110812305 A CN 110812305A CN 201911299795 A CN201911299795 A CN 201911299795A CN 110812305 A CN110812305 A CN 110812305A
- Authority
- CN
- China
- Prior art keywords
- parts
- phase
- component
- stirring
- eye cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 28
- 239000006071 cream Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 52
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 25
- 229940081733 cetearyl alcohol Drugs 0.000 claims abstract description 18
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 18
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 10
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 10
- 235000019698 starch Nutrition 0.000 claims abstract description 10
- 239000008107 starch Substances 0.000 claims abstract description 10
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 10
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 9
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 claims abstract description 9
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 9
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 claims abstract description 9
- 229940101267 panthenol Drugs 0.000 claims abstract description 9
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 9
- 239000011619 pantothenol Substances 0.000 claims abstract description 9
- 150000008105 phosphatidylcholines Chemical class 0.000 claims abstract description 9
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 8
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 3
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 3
- 244000241235 Citrullus lanatus Species 0.000 claims abstract description 3
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 77
- 238000001816 cooling Methods 0.000 claims description 43
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 22
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 16
- 230000001804 emulsifying effect Effects 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 229940100460 peg-100 stearate Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 102000016942 Elastin Human genes 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 241000219739 Lens Species 0.000 claims description 8
- 241001506047 Tremella Species 0.000 claims description 8
- 229920002549 elastin Polymers 0.000 claims description 8
- 229930182478 glucoside Natural products 0.000 claims description 8
- 150000008131 glucosides Chemical class 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000000049 pigment Substances 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 8
- 238000007599 discharging Methods 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 6
- 238000005086 pumping Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229940041984 dextran 1 Drugs 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229940075529 glyceryl stearate Drugs 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 244000043158 Lens esculenta Species 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 7
- 238000010583 slow cooling Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an anti-wrinkle eye cream which is prepared from the following raw materials, by weight, 8-15 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 5-10 parts of polydimethylsiloxane, 0.5-1.5 parts of cetearyl alcohol, 0.2-1 part of hydrogenated phosphatidylcholine, 0.5-1.5 parts of emulsifier, 0.5-1.25 parts of cetearyl alcohol, 25-80 parts of water, 3-8 parts of glycerol, 2-5 parts of nicotinamide, 0.05-0.2 part of sodium polyacrylate grafted starch, 0.01-0.05 part of EDTA disodium and 1-5 parts of panthenol in phase B, 0.5-1.5 parts of β -glucan in phase C, 0.6-2.4 parts of glycerol, 0.1-0.4 part of watermelon fruit extract, 0.1-0.4 part of lentil fruit extract, 0.1-0.4 part of PCA phase extract, 0.1-0.5-0.2.4 part of PCA phase component, 0.5-0.5 part of PCA part of sodium, 0.5-1.5 part of PCA component, 0.5-1.5 part of internal energy content of hydrolyzed protein and 0.5-1.5 week internal energy content of the internal wrinkle reducing peptide in the composition.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to anti-wrinkle eye cream and a preparation process thereof.
Background
The periphery of the eyes is one of the thinnest areas of the human skin, sweat glands and fat glands are rarely distributed, and the skin is very delicate compared with the skin of other parts of the face. Asian women who are 30-35 years old face the first years, namely the aging marks around the eyes, so that nursing is definitely needed. The stratum corneum around the eyes is thin, and the skin around the eyes is the thinnest part of the whole human body surface, the thickness is only about 0.5 mm, and is about one fourth of the skin thickness of other parts of the face. Subcutaneous blood vessels are more easily exposed, and dark circles and blood streaks are generated when microcirculation is poor. Periocular sweat glands and sebum secretion are less: better anti-wrinkle moisturizing is needed.
The skin thickness around the eyes is only about 0.5 mm, but at the same time, 22 muscles are concentrated around the eyes, the skin around the eyes is repeatedly stretched and relaxed by the muscles for tens of thousands of movements every day, collagen is rearranged, the elasticity is finally lost along with the lapse of time, and the expression lines are in millions of times and blink, so that the eyes climb on the expression lines and become deeper and deeper.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides anti-wrinkle eye cream and a preparation process thereof.
The purpose of the invention is realized by the following technical scheme:
an anti-wrinkle eye cream is prepared from the following raw materials in parts by weight:
phase A component: 8-15 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 5-10 parts of polydimethylsiloxane, 0.5-1.5 parts of cetearyl alcohol, 0.2-1 part of hydrogenated phosphatidylcholine, 0.5-1.5 parts of emulsifier, 0.5-1.25 parts of cetearyl alcohol and 0.5-1.25 parts of cetearyl glucoside;
phase B component: 25-80 parts of water, 3-8 parts of glycerol, 2-5 parts of nicotinamide, 0.05-0.2 part of sodium polyacrylate grafted starch, 0.01-0.05 part of disodium EDTA and 1-5 parts of panthenol;
phase C component comprising β -glucan 0.5-1.5 parts, glycerin 0.6-2.4 parts, watermelon fruit extract 0.1-0.4 part, lentil fruit extract 0.1-0.4 part, sodium PCA 0.1-0.4 part, apple fruit extract 0.1-0.4 part, hydrolyzed elastin 0.5-5 parts, oat kernel extract 0.3-1.5 parts, hexapeptide-90.1-0.5 part, butanediol 0.1-0.5 part, and water 0.8-4 parts;
phase D component: 0.01-0.02 part of essence, 0.01-0.03 part of pigment and 0.01-0.03 part of preservative;
phase E component: 3-8 parts of butanediol and 0.2-0.4 part of tremella polysaccharide.
Further, the anti-wrinkle eye cream is prepared from the following raw materials in parts by weight:
phase A component: 12 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 8 parts of polydimethylsiloxane, 1 part of cetearyl alcohol, 0.6 part of hydrogenated phosphatidylcholine, 1 part of emulsifier, 0.7 part of cetearyl alcohol and 1 part of cetearyl glucoside;
phase B component: 50 parts of water, 5 parts of glycerol, 4 parts of nicotinamide, 0.1 part of sodium polyacrylate grafted starch, 0.03 part of EDTA disodium and 3 parts of panthenol;
phase C component comprising β -dextran 1 part, glycerol 0.5 part, pulp Citrulli fruit extract 0.5 part, lentil fruit extract 0.5 part, sodium PCA 0.5 part, fructus Mali Pumilae extract 0.5 part, hydrolyzed elastin 2.5 parts, herba Avenae Fatuae kernel extract 0.9 part, hexapeptide-91.5 part, and butanediol 1.5 part;
phase D component: 0.015 part of essence, 0.02 part of pigment and 0.02 part of preservative;
phase E component: 5.5 parts of butanediol and 0.3 part of tremella polysaccharide.
Further, the emulsifier is a mixture of glycerol stearate and PEG-100 stearate, and the volume ratio of the glycerol stearate to the PEG-100 stearate is 1: 1.
The preparation process of the anti-wrinkle eye cream comprises the following steps:
s1, heating the phase A component to 90-100 ℃, preserving heat for 15-25 min, slowly cooling to 70-80 ℃, and stirring until the phase A component is completely dissolved;
s2, heating the phase B component to 90-100 ℃, preserving heat for 15-25 min, slowly cooling to 70-80 ℃, adding the phase E component, and stirring until the phase E component is completely dissolved;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 10-20 min, homogenizing for 5-10 min, stirring uniformly, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the C phase component, and uniformly stirring;
s5, cooling to 40 ℃, adding the phase D component, and uniformly stirring;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
Further, in the step S1 and the step S2, the temperature reduction speed of the slow temperature reduction is 0.2-0.4 ℃/min.
Further, in the step S1 and the step S2, the stirring speed is 20 to 40 rpm.
Further, in the step S3, the stirring speed is 50-80 rpm, and the vacuum degree of vacuum defoaming is 0.001-0.005 MPa.
Further, in the step S4 and the step S5, the stirring speed is 120 to 180 rpm.
Further, during stirring, a positive and negative alternating stirring method is adopted for stirring, and the stirring direction is alternated for 1-3 min every time.
The invention has the following advantages:
1. the invention adopts vinyl dimethyl silicone polymer/polymethyl siloxane silsesquioxane crosslinked polymer and polyacrylic acid grafted starch, and the two compounds are added on the formula, so that the formula has no oily feeling and no oily luster, has velvet feeling in touch, looks dull, can effectively scatter light, and has the effect of filling and softening wrinkles.
2. The product of the invention adopts AcquaCell to match with Coollaxyl in terms of efficacy, can reduce fine lines within 24 hours after being used, can increase intracellular water within 2 weeks, and can reduce the length and depth of wrinkles.
Detailed Description
The invention is further described below with reference to examples, but the scope of the invention is not limited to the following.
[ example 1 ]:
an anti-wrinkle eye cream and a preparation process thereof are prepared from the following raw materials in parts by weight:
phase A component: vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane crosspolymer 15 parts, polydimethylsiloxane 5 parts, cetearyl alcohol 1.5 parts, hydrogenated phosphatidylcholine 0.2 parts, emulsifier 1.5 parts, cetearyl alcohol 0.5 parts, cetearyl glucoside 1.25 parts;
phase B component: 25 parts of water, 8 parts of glycerol, 2 parts of nicotinamide, 0.2 part of sodium polyacrylate grafted starch, 0.01 part of EDTA disodium and 5 parts of panthenol;
phase C component comprising β -dextran 0.5 parts, glycerol 2.4 parts, pulp Citrulli fruit extract 0.1 part, lentil fruit extract 0.4 parts, sodium PCA 0.1 part, apple fruit extract 0.4 parts, hydrolyzed elastin 0.5 parts, oat kernel extract 1.5 parts, hexapeptide-90.1 parts, butanediol 0.5 parts, and water 0.8 parts;
phase D component: 0.01 part of essence, 0.03 part of pigment and 0.01 part of preservative;
phase E component: 8 parts of butanediol and 0.2 part of tremella polysaccharide.
Further, the emulsifier is a mixture of glycerol stearate and PEG-100 stearate, and the volume ratio of the glycerol stearate to the PEG-100 stearate is 1: 1.
The preparation process of the anti-wrinkle eye cream comprises the following steps:
s1, heating the phase A component to 90 ℃, preserving heat for 25min, slowly cooling to 70 ℃, wherein the cooling speed of slow cooling is 0.4 ℃/min, stirring until complete dissolution is achieved, and the stirring speed is 20 rpm;
s2, heating the phase B component to 100 ℃, preserving heat for 15min, slowly cooling to 80 ℃, slowly cooling at a cooling speed of 0.2 ℃/min, adding the phase E component, and stirring until the phase B component is completely dissolved at a stirring speed of 40 rpm;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 10min, homogenizing for 10min, stirring uniformly at the stirring speed of 50rpm under the vacuum defoaming degree of 0.005Mpa, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the phase C component, and uniformly stirring at the stirring speed of 120 rpm;
s5, cooling to 40 ℃, adding the phase D component, and uniformly stirring at the stirring speed of 180 rpm;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
Further, during stirring, the stirring was carried out by a forward and reverse alternate stirring method, with the stirring direction being alternated every 1 min.
[ example 2 ]:
an anti-wrinkle eye cream is prepared from the following raw materials in parts by weight:
phase A component: 12 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 8 parts of polydimethylsiloxane, 1 part of cetearyl alcohol, 0.6 part of hydrogenated phosphatidylcholine, 1 part of emulsifier, 0.7 part of cetearyl alcohol and 1 part of cetearyl glucoside;
phase B component: 50 parts of water, 5 parts of glycerol, 4 parts of nicotinamide, 0.1 part of sodium polyacrylate grafted starch, 0.03 part of EDTA disodium and 3 parts of panthenol;
phase C component comprising β -dextran 1 part, glycerol 1.5 parts, pulp Citrulli fruit extract 0.25 part, lentil fruit extract 0.25 part, sodium PCA 0.25 part, apple fruit extract 0.25 part, hydrolyzed elastin 2.5 parts, oat kernel extract 0.9 part, hexapeptide-90.3 parts, butanediol 0.3 part, and water 2.4 parts;
phase D component: 0.015 part of essence, 0.02 part of pigment and 0.02 part of preservative;
phase E component: 5.5 parts of butanediol and 0.3 part of tremella polysaccharide.
Further, the emulsifier is a mixture of glycerol stearate and PEG-100 stearate, and the volume ratio of the glycerol stearate to the PEG-100 stearate is 1: 1.
The preparation process of the anti-wrinkle eye cream comprises the following steps:
s1, heating the phase A component to 95 ℃, preserving heat for 20min, slowly cooling to 75 ℃, wherein the cooling speed of slow cooling is 0.3 ℃/min, stirring until complete dissolution is achieved, and the stirring speed is 30 rpm;
s2, heating the phase B component to 95 ℃, preserving heat for 20min, slowly cooling to 75 ℃, slowly cooling at the speed of 0.3 ℃/min, adding the phase E component, and stirring until the phase B component is completely dissolved at the speed of 30 rpm;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 15min, homogenizing for 7min, stirring uniformly at the stirring speed of 65rpm under the vacuum defoaming degree of 0.003Mpa, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the phase C component, and uniformly stirring at the stirring speed of 150 rpm;
s5, when the temperature is reduced to 40 ℃, adding the phase D component, and stirring uniformly at the stirring speed of 150 rpm;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
Further, during stirring, the stirring was carried out by a forward and reverse alternate stirring method, with the stirring direction being alternated every 2 min.
[ example 3 ]:
an anti-wrinkle eye cream is prepared from the following raw materials in parts by weight:
phase A component: 10 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 8 parts of polydimethylsiloxane, 0.8 part of cetearyl alcohol, 1 part of hydrogenated phosphatidylcholine, 0.5 part of emulsifier, 0.7 part of cetearyl alcohol and 0.9 part of cetearyl glucoside;
phase B component: 60 parts of water, 6 parts of glycerol, 4 parts of nicotinamide, 0.09 part of sodium polyacrylate grafted starch, 0.04 part of EDTA disodium and 2 parts of panthenol;
phase C component comprising β -dextran 0.9 parts, glycerol 0.8 parts, pulp Citrulli fruit extract 0.3 parts, lentil fruit extract 0.3 parts, sodium PCA 0.3 parts, apple fruit extract 0.3 parts, hydrolyzed elastin 3 parts, oat kernel extract 0.9 parts, hexapeptide-90.4 parts, butanediol 0.2 parts, and water 3 parts;
phase D component: 0.015 part of essence, 0.02 part of pigment and 0.02 part of preservative;
phase E component: 4 parts of butanediol and 0.4 part of tremella polysaccharide.
Further, the emulsifier is a mixture of glycerol stearate and PEG-100 stearate, and the volume ratio of the glycerol stearate to the PEG-100 stearate is 1: 1.
The preparation process of the anti-wrinkle eye cream comprises the following steps:
s1, heating the phase A component to 95 ℃, preserving heat for 22min, slowly cooling to 77 ℃, wherein the cooling speed of slow cooling is 0.3 ℃/min, stirring until complete dissolution is achieved, and the stirring speed is 30 rpm;
s2, heating the phase B component to 94 ℃, preserving heat for 22min, slowly cooling to 78 ℃, wherein the cooling speed of slow cooling is 0.3 ℃/min, adding the phase E component, and stirring until the phase B component is completely dissolved, wherein the stirring speed is 30 rpm;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 15min, homogenizing for 6min, stirring uniformly at the stirring speed of 70rpm under the vacuum defoaming degree of 0.004Mpa, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the phase C component, and uniformly stirring at the stirring speed of 160 rpm;
s5, cooling to 40 ℃, adding the phase D component, and uniformly stirring at the stirring speed of 180 rpm;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
Further, during stirring, forward and reverse alternate stirring methods were used, and the stirring direction was alternated every 3 min.
Example 4:
an anti-wrinkle eye cream and a preparation process thereof are prepared from the following raw materials in parts by weight:
phase A component: 8 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 10 parts of polydimethylsiloxane, 0.5 part of cetearyl alcohol, 1 part of hydrogenated phosphatidylcholine, 0.5 part of emulsifier, 1.25 parts of cetearyl alcohol and 0.5 part of cetearyl glucoside;
phase B component: 80 parts of water, 3 parts of glycerol, 5 parts of nicotinamide, 0.05 part of sodium polyacrylate grafted starch, 0.05 part of EDTA disodium and 1 part of panthenol;
phase C component comprising β -dextran 1.5 parts, glycerol 0.6 parts, pulp Citrulli fruit extract 0.4 parts, lentil fruit extract 0.1 parts, sodium PCA 0.4 parts, apple fruit extract 0.1 parts, hydrolyzed elastin 5 parts, oat kernel extract 0.3 parts, hexapeptide-90.5 parts, butanediol 0.1 parts, and water 4 parts;
phase D component: 0.02 part of essence, 0.01 part of pigment and 0.03 part of preservative;
phase E component: 3 parts of butanediol and 0.4 part of tremella polysaccharide.
Further, the emulsifier is a mixture of glycerol stearate and PEG-100 stearate, and the volume ratio of the glycerol stearate to the PEG-100 stearate is 1: 1.
The preparation process of the anti-wrinkle eye cream comprises the following steps:
s1, heating the phase A component to 100 ℃, preserving heat for 15min, slowly cooling to 80 ℃, wherein the cooling speed of slow cooling is 0.2 ℃/min, stirring until complete dissolution is achieved, and the stirring speed is 40 rpm;
s2, heating the phase B component to 90 ℃, preserving heat for 25min, slowly cooling to 70 ℃, wherein the cooling speed of slow cooling is 0.4 ℃/min, adding the phase E component, and stirring until the phase B component is completely dissolved, wherein the stirring speed is 20 rpm;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 20min, homogenizing for 5min, stirring uniformly at the stirring speed of 80rpm under the vacuum defoaming degree of 0.001Mpa, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the phase C component, and uniformly stirring at the stirring speed of 180 rpm;
s5, when the temperature is reduced to 40 ℃, adding the phase D component, and stirring uniformly at the stirring speed of 120 rpm;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
Further, during stirring, forward and reverse alternate stirring methods were used, and the stirring direction was alternated every 3 min.
Some performance index tests were performed on the test products as follows:
1. appearance: light orange cream.
pH value: 4.0-8.5.
3. Heat resistance stability test (45 ℃ C.. times.24 h): and (4) passing.
4. Cold resistance stability test (-15 ℃ C.. times.24 h): and (4) passing.
The product performance evaluation test is as follows:
firstly, skin irritation test:
randomly selecting 40 people, coating 0.5g of the product or blank matrix each time, randomly administering twice a day on the left or right side, performing a self-control test method, and observing and recording the skin reaction phenomenon after 24h and 72 h.
Evaluation of anti-wrinkle efficacy
Test objects:
50 female Asians aged 37-55 years
Pretreatment: subjects stopped various other wrinkle-reducing treatments and avoided direct exposure to sunlight at least 3 days prior to the study, and throughout the study.
The treatment method comprises the following steps:
divided arbitrarily into five groups, twice daily, 2 grams of cream containing the above formulation was applied to the outside of the eyes for a total of 60 days.
Measurement:
a. placing a positioning ring at the canthus (fishtail);
b. the direction of the ring is consistent with the direction of the maximum wrinkle through two marks on the ring;
c. measuring the distance to the corner of the eye (canthus) to ensure that the measurements are consistent each time;
"average height reduction" is calculated as the average of three measurements of the maximum wrinkle height;
e. readings for non-wrinkled areas were used to determine "skin roughness";
f. the height (depth) of the wrinkles can be obtained from the scale reading of the profilometer;
g. the roughness profile can be obtained directly from the reader of the profilometer;
statistical analysis:
a. the mean wrinkle height reduction and the measurement of skin roughness were analyzed by a bilateral test method:
the results of clinical trials of the product of example 2 of the invention are shown in the following table:
the results in the table show that the product of the invention has obvious anti-wrinkle effect, can reduce fine lines within 24 hours of use, can increase intracellular water within 2 weeks, and can reduce the length and depth of wrinkles without allergy.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. An anti-wrinkle eye cream is characterized in that: the feed is prepared from the following raw materials in parts by weight:
phase A component: 8-15 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 5-10 parts of polydimethylsiloxane, 0.5-1.5 parts of cetearyl alcohol, 0.2-1 part of hydrogenated phosphatidylcholine, 0.5-1.5 parts of emulsifier, 0.5-1.25 parts of cetearyl alcohol and 0.5-1.25 parts of cetearyl glucoside;
phase B component: 25-80 parts of water, 3-8 parts of glycerol, 2-5 parts of nicotinamide, 0.05-0.2 part of sodium polyacrylate grafted starch, 0.01-0.05 part of disodium EDTA and 1-5 parts of panthenol;
phase C component comprising β -glucan 0.5-1.5 parts, glycerin 0.6-2.4 parts, watermelon fruit extract 0.1-0.4 part, lentil fruit extract 0.1-0.4 part, sodium PCA 0.1-0.4 part, apple fruit extract 0.1-0.4 part, hydrolyzed elastin 0.5-5 parts, oat kernel extract 0.3-1.5 parts, hexapeptide-90.1-0.5 part, butanediol 0.1-0.5 part, and water 0.8-4 parts;
phase D component: 0.01-0.02 part of essence, 0.01-0.03 part of pigment and 0.01-0.03 part of preservative;
phase E component: 3-8 parts of butanediol and 0.2-0.4 part of tremella polysaccharide.
2. The anti-wrinkle eye cream according to claim 1, wherein: the feed is prepared from the following raw materials in parts by weight:
phase A component: 12 parts of vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, 8 parts of polydimethylsiloxane, 1 part of cetearyl alcohol, 0.6 part of hydrogenated phosphatidylcholine, 1 part of emulsifier, 0.7 part of cetearyl alcohol and 1 part of cetearyl glucoside;
phase B component: 50 parts of water, 5 parts of glycerol, 4 parts of nicotinamide, 0.1 part of sodium polyacrylate grafted starch, 0.03 part of EDTA disodium and 3 parts of panthenol;
phase C component comprising β -dextran 1 part, glycerol 1.5 parts, pulp Citrulli fruit extract 0.25 part, lentil fruit extract 0.25 part, sodium PCA 0.25 part, apple fruit extract 0.25 part, hydrolyzed elastin 2.5 parts, oat kernel extract 0.9 part, hexapeptide-90.3 parts, butanediol 0.3 part, and water 2.4 parts;
phase D component: 0.015 part of essence, 0.02 part of pigment and 0.02 part of preservative;
phase E component: 5.5 parts of butanediol and 0.3 part of tremella polysaccharide.
3. An anti-wrinkle eye cream according to claim 1 or 2, wherein: the emulsifier is a mixture of glyceryl stearate and PEG-100 stearate, and the volume ratio of the glyceryl stearate to the PEG-100 stearate is 1: 1.
4. The process for preparing the anti-wrinkle eye cream as claimed in any one of claims 1 to 4, wherein the process comprises the following steps: the method comprises the following steps:
s1, heating the phase A component to 90-100 ℃, preserving heat for 15-25 min, slowly cooling to 70-80 ℃, and stirring until the phase A component is completely dissolved;
s2, heating the phase B component to 90-100 ℃, preserving heat for 15-25 min, slowly cooling to 70-80 ℃, adding the phase E component, and stirring until the phase E component is completely dissolved;
s3, adding the mixed phase obtained in the step S2 into an emulsifying pot, pumping the phase A component, pre-emulsifying for 10-20 min, homogenizing for 5-10 min, stirring uniformly, vacuumizing, defoaming and cooling;
s4, cooling to 50 ℃, adding the C phase component, and uniformly stirring;
s5, cooling to 40 ℃, adding the phase D component, and uniformly stirring;
and S6, cooling to normal temperature, carrying out physical and chemical index inspection, and discharging after the product is qualified.
5. The manufacturing process of the anti-wrinkle eye cream according to claim 4, characterized in that: in the steps S1 and S2, the temperature reduction speed of the slow temperature reduction is 0.2-0.4 ℃/min.
6. The manufacturing process of the anti-wrinkle eye cream according to claim 5, characterized in that: in the step S1 and the step S2, the stirring speed is 20 to 40 rpm.
7. The manufacturing process of the anti-wrinkle eye cream according to claim 4, characterized in that: in the step S3, the stirring speed is 50-80 rpm, and the vacuum degree of vacuum defoaming is 0.001-0.005 Mpa.
8. The manufacturing process of the anti-wrinkle eye cream according to claim 4, characterized in that: in the step S4 and the step S5, the stirring speed is 120-180 rpm.
9. The manufacturing process of the anti-wrinkle eye cream according to claim 8, characterized in that: during stirring, a positive and negative alternate stirring method is adopted for stirring, and the stirring direction is alternated for 1-3 min every time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911299795.XA CN110812305A (en) | 2019-12-17 | 2019-12-17 | Anti-wrinkle eye cream and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911299795.XA CN110812305A (en) | 2019-12-17 | 2019-12-17 | Anti-wrinkle eye cream and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110812305A true CN110812305A (en) | 2020-02-21 |
Family
ID=69546176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911299795.XA Pending CN110812305A (en) | 2019-12-17 | 2019-12-17 | Anti-wrinkle eye cream and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110812305A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111616968A (en) * | 2020-06-10 | 2020-09-04 | 上海中翊日化有限公司 | Composition for Guifu ointment and preparation method, use method and application thereof |
| CN112353707A (en) * | 2020-11-30 | 2021-02-12 | 重庆中佳信生物科技有限公司 | Face cream and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147590A (en) * | 2015-10-19 | 2015-12-16 | 广州科玛生物科技有限公司 | Anti-wrinkle eye cream and preparation method thereof |
-
2019
- 2019-12-17 CN CN201911299795.XA patent/CN110812305A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147590A (en) * | 2015-10-19 | 2015-12-16 | 广州科玛生物科技有限公司 | Anti-wrinkle eye cream and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 广州市澳莱化妆品有限公司: "仙尚花园富勒烯逆龄舒缓眼霜", 《国产非特殊用途化妆品备案服务平台》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111616968A (en) * | 2020-06-10 | 2020-09-04 | 上海中翊日化有限公司 | Composition for Guifu ointment and preparation method, use method and application thereof |
| CN112353707A (en) * | 2020-11-30 | 2021-02-12 | 重庆中佳信生物科技有限公司 | Face cream and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101849898B (en) | Eye creams and preparation method thereof | |
| CN110812305A (en) | Anti-wrinkle eye cream and preparation process thereof | |
| CN103919711B (en) | A kind of anti-ageing whitening cream of oolong tea and manufacture method thereof | |
| CN107822946A (en) | A kind of painting type water light porcelain flesh Essence and preparation method thereof | |
| KR102450173B1 (en) | Cosmetic composition for moisturizing facial skin and alleviating swelling | |
| CN108113914A (en) | A kind of essence cream for not adding essence preservative and preparation method thereof | |
| CN112891286A (en) | Beautifying and firming repair cream and preparation method thereof | |
| CN114287631A (en) | A kind of small molecular sodium hyaluronate, small molecular sodium hyaluronate composition for improving skin aging and sensitivity and application thereof | |
| CN113081874A (en) | Personalized beauty treatment method based on skin | |
| CN113425639B (en) | Antioxidant composition, application thereof and product | |
| CN115844748A (en) | Eye composition and preparation method and application thereof | |
| CN114028291A (en) | Composition for improving dark eye circles and preparation method and application thereof | |
| CN118948726A (en) | Soothing anti-aging composition, preparation method and application | |
| CN115400068B (en) | Repairing and soothing composition and water, milk and cream containing same | |
| CN111096929A (en) | Essence with repairing and moistening effects and preparation method and application thereof | |
| CN105998617A (en) | Externally applied traditional Chinese medicine extract with effect of soothing senile pruritus, as well as preparation method and application thereof | |
| EP3094303B1 (en) | Composition for the effects of winter aging on the skin | |
| CN118319810A (en) | Body skin soothing essence liquid and preparation method thereof | |
| CN114306116A (en) | Skin-brightening cream for sensitive muscles and preparation method thereof | |
| CN117860647A (en) | Mask liquid composition with multiple effects and preparation method and application thereof | |
| CN110812300A (en) | Weight-losing and moisturizing body lotion for promoting subcutaneous fat metabolism | |
| CN106924057B (en) | Small micelle water cosmetic for promoting rapid transdermal absorption of water-soluble substances | |
| KR20030087680A (en) | Composition for external application to the skin containing D-Fructose 1,6 diphosphate | |
| CN111407695A (en) | Sea-buckthorn water and preparation method and application thereof | |
| CN108888561B (en) | Whitening composition and cosmetic prepared from same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200221 |